Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Headquartered in Bedford, Massachusetts, Anika Therapeutics, Inc. develops, manufa...
Headquartered in Bedford, Massachusetts, Anika ...
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics co...
CareDx, Inc., headquartered in Brisbane, Califo...
MediWound is a fully integrated biopharmaceutical company focused on developing, m...
MediWound is a fully integrated biopharmaceutic...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
Join the National Investor Network and get the latest information with your interests in mind.